HIV fusion and its inhibition in antiretroviral therapy
- 19 August 2004
- journal article
- review article
- Published by Wiley in Reviews in Medical Virology
- Vol. 14 (5), 321-337
- https://doi.org/10.1002/rmv.440
Abstract
The end of the twentieth century saw dramatic improvements in the prognosis of HIV infection brought about by the introduction of new agents (the protease inhibitors and the non‐nucleoside reverse transcriptase inhibitors) and their use in highly active combinations. However, the durability of these combination treatments is limited by a number of factors including adverse effects and extensive intra‐class cross‐resistance so that new antiretrovirals acting on alternative targets and having improved systemic tolerability profiles are required. The HIV binding and entry process offers several potential targets for antiviral interaction. These include gp120 binding to CD4 and to chemokine co‐receptor molecules as well as the fusion process itself, which involves interactions between two leucine zipper‐like 4‐3 repeat regions within gp41 known as heptad repeat (HR)1 and HR2. Peptides such as enfuvirtide (formerly DP178 or T‐20), that mimic the HR2 region of gp41, inhibit HIV‐1 by a mechanism that is thought to involve competitive binding to HR1. This review summarises the clinical development of enfuvirtide, providing an overview of the pharmacokinetic, efficacy and safety data in various patient populations, and also considers the evidence for the key role of genotypic changes in the HR1 region (amino acids 36–45) in determining viral susceptibility to inhibition by enfuvirtide. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 78 references indexed in Scilit:
- Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 WeeksHIV Research & Clinical Practice, 2003
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyAIDS, 2003
- Subcutaneous Injection Survey: Psychometric Evaluation of a Treatment Satisfaction Instrument Associated with a Novel HIV MedicationHIV Research & Clinical Practice, 2002
- The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected AdultsAIDS Research and Human Retroviruses, 2002
- Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency VirusThe New England Journal of Medicine, 1995
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Structure of influenza haemagglutinin at the pH of membrane fusionNature, 1994
- A spring-loaded mechanism for the conformational change of influenza hemagglutininCell, 1993
- Retroviral Envelope Glycoproteins Contain a "Leucine Zipper"-like RepeatAIDS Research and Human Retroviruses, 1990
- A General Model for the Transmembrane Proteins of HIV and Other RetrovirusesAIDS Research and Human Retroviruses, 1989